CONQUEST
4.4.2024 12:19:30 CEST | Business Wire | Press release
Conquest enters the Finnish renewable power market with the acquisition from BHM Renewables (a BHM group company) of a 182MW onshore wind portfolio developed by Winda Energy and the implementation of a broader strategic partnership towards further extensions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404783244/en/
Shutterstock, Wind Portfolio in Finland
Conquest, a fund manager focusing on the infrastructures of the energy transition in Europe, through its fund Conquest Infrastructure SLP – Sustainable 2, has completed the concomitant acquisitions of two wind farms developed by Winda Energy, the Finnish renewable energy developer majority-owned by Czech BHM Renewables, part of the investment firm BHM group. The two onshore wind projects have a combined capacity of 182MW. Furthermore, the cooperation encompasses additional onshore wind projects totalling 500MW.
The transaction allows Conquest to expand its renewable power platform and its footprint in the Nordics market, while maintaining a well-balanced and diversified approach towards investments targeted to the energy transition in Europe. The transaction represents an expected phased total investment of approximately 1 billion euros, to be gradually deployed between 2024 and 2028, offering a fully green investment in one of Europe’s most stable and robust economies.
The first two wind projects are at an advanced stage of development, with the first 182MW expected to reach ready-to-build by Q4 2024 and the rest expected to reach the same stage by Q4 2025. Winda Energy Oy will complete the development and manage the construction with expected start dates of commercial operations ranging from 2026 to 2028 for the portfolio.
Frederic Palanque, Founder and Managing Director of Conquest said: “Conquest is thrilled to enter, in partnership with Winda Energy, in sustainable real assets in a market recognized for its robust renewable energy fundamentals and its ambitious net zero roadmap.”
“We are happy to cooperate with Conquest, a dynamic and reliable partner on our growth journey. The transaction secures the completion of some of our flagship projects over the next years, enabling us to extend our contribution to Finland’s green energy transition.”, says Tuomas Hooli, CEO of Winda Energy.
Michal Prause, Associate Partner at BHM Renewables, said: “We are extremely pleased with the outcome of the transaction, reflecting the deep development skills, which our affiliate Winda has been demonstrating on the Finnish renewable power market over the years. We are looking forward to the strategic partnership with the highly professional asset management and investment teams of Conquest.”
ABOUT
Conquest
Established in 2012, Conquest is an alternative asset management firm invested in sustainable and long-term value stemming from European infrastructures. Conquest invests in and operates long-life, high- quality assets and businesses on behalf of its clients, which range from large institutional investors to single-family offices. With a team of 20 collaborators, based in Dublin and Paris, the firm manages assets worth circa 500 million euros and 25 investments across Europe.
BHM group
BHM group is a rapidly expending European investment firm that manages dozens of European companies in Europe. In the energy sector, BHM group is focused on investments in renewable energy sources, with an emphasis on wind and solar energy, and is active in six countries in Central Europe and Scandinavia. Due to its extensive experience and many successful projects, BHM group companies can provide comprehensive services, encompassing development, construction, and operation. BHM group focuses on long-term and stable partnerships that take into account healthy economic growth and are in line with internationally recognized standards of social responsibility and sustainability.
Winda Energy
Winda Energy Oy is a leading Finnish renewable energy project developer with its current development portfolio consisting of 3 GW of onshore wind and 1 GW of solar PV across Finland. Winda Energy has extensive experience in the renewable sector and takes projects from their initial design to the end of construction, most recently completing the construction of 200 MW of onshore wind in 2023. Winda Energy is majority owned by BHM group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404783244/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom